Advertisement

Pharmacy World and Science

, Volume 19, Issue 6, pp 269–274 | Cite as

A postmarketing study of flunarizine in migraine and vertigo

  • G.H. de Bock
  • J. Eelhart
  • H.W.J. van Marwijk
  • T.P. Tromp
  • M.P. Springer
Article

Abstract

This prospective, open multi-centre study on flunarizine focused on the risk/benefit ratio of the use of flunarizine in the prophylaxis of migraine and in the treatment of vertigo, due to disorder of the vestibular system. The assessment of risks focused on the incidence of new events of depression and/or extrapyramidal syndrome during flunarizine treatment. For migraine, flunarizine was compared to propranolol in 686 patients; for vertigo, flunarizine was compared to betahistine in 198 patients. The incidence of depression during follow-up in this study was significantly higher in the flunarizine group than in the propranolol group in the condition of migraine. There were no observations of an extrapyramidal syndrome. There was a suggestion that flunarizine has more benefits than propranolol in the condition of migraine, and that betahistine has more benefit than flunarizine in the condition of vertigo. Differences in dosages could possibly explain these differences.

flunarizine propranolol betahistine depression general practitioner pharmacovigilence side-effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27:6–44.Google Scholar
  2. 2.
    Verhaeghe R, Verstraete M. Drugs acting on the cerebral and peripheral circulations. In: Dukes MNG, ed. Meyler's side-effects of drugs. Elseviers Science Publishers BV, 1992.Google Scholar
  3. 3.
    Micheli FE, Pardal MM, Giannaula R et al. Movement disorders and depression due to flunarizien and cinnarizine. Mov Disord 1989;4:139–46.Google Scholar
  4. 4.
    Benvenuti F, Baroni A, Bandinelli S, Ferrucci L, Corradetti R, Pantaleo T. Flunarizien-induced parkinsonism in the elderly. J Clin Pharmacol 1988;28:600–8.Google Scholar
  5. 5.
    Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol 1988;28:208–11.Google Scholar
  6. 6.
    Moretti A, Lucantoni C. Flunarizine-induced parkinsonism: clinical report. Ital J Neurol Sci 1988;9:295–7.Google Scholar
  7. 7.
    Di Rosa AE, Morgante L, Meduri M et al. Parkinson-like side effects during prolonged treatment with flunarizine. Funct Neurol 1987;2:47–50.Google Scholar
  8. 8.
    Micheli F, Pardal MF, Gatto M et al. Flunarizine-and cinnarizine-induced extrapyramidal reactions. Neurology 1987;37:881–4.Google Scholar
  9. 9.
    Chouza C, Scaramelli A, Caamano JL, De Medina O, Aljanati R, Romero S. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986;ii:1303–4.Google Scholar
  10. 10.
    Cappella D, Laporte JR, Castel JM, Tristan C, Cos A, Morales-Olivas FJ. Parkinsonism, tremor and depression induced by cinnarizine and flunarizine, Brit Med J 1988;297:722–3.Google Scholar
  11. 11.
    Assmann VCCA, Perquin WVM, Touw DJ. Extrapiramidal dyskinesia due to flunarizine. Ned Tijdschr Geneesk 1988;132:1940–2.Google Scholar
  12. 12.
    Petri H, De Vet HCW, Naus J, Urquhart J. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988;7:1171–5.Google Scholar
  13. 13.
    Petri H, Leufkens H, Naus J, Silkens R, Van Hessen P, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990;43:433–9.Google Scholar
  14. 14.
    Germans restrict flunarizine use. SCRIP 1991;1599:23.Google Scholar
  15. 15.
    CPMP restricts flunarizine indications. SCRIP 1991;1601:22.Google Scholar
  16. 16.
    Verspeelt J, De Locht P, Amery WK. Post-marketing study of the use of flunarizine in vestibular vertigo and in migraine. Accepted for publication in Eur J Clin Pharm.Google Scholar
  17. 17.
    International classification of diseases. Manual of the international statistical classification of diseases, injuries, and causes of death. Based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly. Geneva, World Health Organization. 1977 (Volumes 1 and 2).Google Scholar
  18. 18.
    Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific Publications, 1987 (second edition).Google Scholar
  19. 19.
    Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990;150:2286–90.Google Scholar
  20. 20.
    Griffin SJ, Friedman MJ. Depressive symptoms in propranolol users. J Clin Psychiatry 1986;47:543–7.Google Scholar
  21. 21.
    Cremona-Barbaro A. Propranolol and depression [letter]. Lancet 1983;i:185.Google Scholar
  22. 22.
    Van Marwijk HWJ, Grundmeijer HGLM, Brueren MM et al. NHG-standaard depressie. Huisarts Wet 1994.Google Scholar
  23. 23.
    Breslau N, Davis GC, Schultz LR, Peterson EL. Migraine and major depression: a longitudinal study. Headache 1994;34:387–93.Google Scholar
  24. 24.
    Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Arch Gen Psychiatry 1990;47:849–53.Google Scholar
  25. 25.
    Negrotti A, Calzetti S, Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited suspectibility. Neurotoxicology 1992;13:261–4.Google Scholar
  26. 26.
    Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine. Lancet 1986;853–4.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • G.H. de Bock
    • 1
  • J. Eelhart
    • 2
  • H.W.J. van Marwijk
    • 1
  • T.P. Tromp
    • 2
  • M.P. Springer
    • 1
  1. 1.Department of General PracticeLeiden UniversityLeidenThe Netherlands
  2. 2.IMS Clinical ServicesThe Netherlands

Personalised recommendations